Provider profile

Resilience.

Biologics CDMOs

Resilience (National Resilience) describes cell line, process, analytical and formulation development, mammalian drug substance manufacturing of monoclonal antibodies and recombinant proteins in single-use bioreactors, and sterile fill/finish, from preclinical to commercial supply. It lists headquarters in Blue Ash, Ohio, drug substance and vial filling near Toronto, and drug product at West Chester, Ohio.

Website: resilience.com (opens in a new tab)
Sources reviewed: November 3, 2026 · Source pages re-checked within 4 months
First published: November 3, 2026

This profile summarizes what public sources state about the provider, mostly its own website. It is not an audit, qualification or endorsement by ArgusBio. Confirm capabilities directly with the provider before contracting.

Services and capabilities

Analytical development and QC testing3,4
Bioconjugation (ADC)1Non-cytotoxic chemical and enzymatic conjugation only; cytotoxic ADC conjugation is not documented
Cell line development3Listed under upstream drug substance capabilities; master cell banks are produced at the Toronto site
Formulation development2,5
GMP drug product manufacturing5,6
GMP drug substance manufacturing1,2Biologics drug substance is manufactured at the Toronto, Ontario site (single-use bioreactors 50 L to 2,000 L)
Process development1,2Stated for the Toronto, Ontario site
Stability studies1,3,4
Technology transfer1,3,4

Platforms and methods

Mammalian cell culture1Stated for drug substance manufacturing at the Toronto site
Single-use bioreactors3,5

Drug substance / drug product

Drug product4,5
Drug substance1,2Stated for the Toronto, Ontario site

Development experience

Development stage

Commercial3,5,6
Phase 12Stage coverage stated for development and analytical services
Phase 22Stage coverage stated for development and analytical services
Phase 32Stage coverage stated for development and analytical services
Preclinical2,5Stage coverage stated for development and analytical services

Modality

Monoclonal antibodies3,4,5
Peptides4Sterile drug product (fill/finish) only
Recombinant proteins3,4,5
Small molecules4Sterile drug product (fill/finish) only

Locations

Blue Ash, United States · Headquarters8Global headquarters; the Blue Ash site also handles commercial packaging, with inspection, device assembly and labeling planned through 2027
Mississauga, Canada · Manufacturing site1Listed by the company as its Toronto, Ontario site: process and analytical development, biologics drug substance (mammalian, single-use up to 2,000 L), formulation and aseptic vial filling
Hamilton, United States · Manufacturing site7Listed by the company as its West Chester, Ohio site: sterile drug product (formulation, aseptic fill/finish, inspection, device assembly, packaging)

Quality and regulatory

The provider’s own materials state that it works to, or holds, the following. ArgusBio has not inspected or audited these claims.

GMP / cGMP1,7Stated for the Toronto facility

Unknowns and questions to ask

Public sources rarely establish what matters most for a specific project. Confirm directly:

Available capacity, slot timing and scale for your next campaign
Recent experience with your specific modality and expression system or chemistry
Regulatory inspection history of the specific site that would manufacture your product
Technology-transfer approach, timeline and who owns the resulting process knowledge
Analytical and QC release testing done in-house versus subcontracted
Quality agreement terms, batch-failure responsibility and change-order mechanics

Choosing a CDMO: a practical guide

Evidence and sources

1Toronto, ON Biologics Manufacturing Facility | Resilience (opens in a new tab)National Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
2Process and Analytical Development CDMO | Resilience (opens in a new tab)National Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
3Biologics Drug Substance Manufacturing CDMO | Resilience (opens in a new tab)National Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
4Sterile Drug Product Manufacturing CDMO | Resilience (opens in a new tab)National Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
5Biologics & Sterile Drug Product CDMO | Resilience (opens in a new tab)National Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
6Biologics CDMO Manufacturing Facilities | Resilience (opens in a new tab)National Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
7West Chester, OH Sterile Drug Product Facility | Resilience (opens in a new tab)National Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
8Contact Resilience | Biologics Manufacturing CDMO (opens in a new tab)Resilience · Provider website · retrieved November 3, 2026 · last checked November 3, 2026

“Last checked” means we confirmed the page was still available and still contained the cited statement. It does not mean ArgusBio verified the provider or its capabilities.

Something out of date or wrong? Request a correction. Corrections are reviewed against public sources before publication.

Contact

Contact the provider directly through its public contact page (opens in a new tab). ArgusBio does not forward inquiries to providers and does not receive referral fees.

Compare with other biologics cdmos providers

ArgusBio sourcing

Need help evaluating this provider or comparing alternatives.

Discuss your sourcing need with ArgusBio. We can help define the scope, identify comparable alternatives and organize proposals so the decision stays yours.

Discuss a sourcing need

We work for the biotech, not the vendor. Vendors do not pay for inclusion or placement.